Extracorporeal shockwave therapy for diabetic foot ulcers: a feasibility study.

Diabetes Diabetic foot ulcer Extracorporeal shockwave therapy Shockwave Ulcer Wound Wound care Wound dressing Wound healing

Journal

Journal of wound care
ISSN: 0969-0700
Titre abrégé: J Wound Care
Pays: England
ID NLM: 9417080

Informations de publication

Date de publication:
02 Mar 2023
Historique:
entrez: 17 3 2023
pubmed: 18 3 2023
medline: 22 3 2023
Statut: ppublish

Résumé

The purpose of this study was to assess the feasibility of delivering extracorporeal shockwave therapy (ESWT) to patients with diabetic foot ulcers (DFUs). It also aimed to explore any potential clinical effect of ESWT on wound healing and investigate whether ESWT offers any patient-reported benefits. In this single-centre, mixed methods feasibility study, patients with a DFU who met the eligibility criteria underwent ESWT three times over a seven-day period. Primary outcome was feasibility of delivering the intervention. Secondary outcomes included wound size, number of DFUs healed at 12 weeks and quality of life (QoL). Semi-structured interviews explored participants' experience of undergoing ESWT. Of 106 patients screened, 24 (22.6%) were recruited. Following recruitment, two patients were withdrawn from the study with 22 patients included in the final analysis. The mean attendance at clinic was 90.9% and 65.1% for follow-up. The mean score for acceptability and tolerability was 9.86±0.48 (95% confidence interval (CI): 9.62-10.01) and 9.15±2.57 (95% CI: 7.87-10.42), respectively. There were no serious adverse events or side-effects. Of the DFUs, 45.5% healed during follow-up and QoL scores improved until eight weeks. Key themes identified from the qualitative interviews were: desire for fast healing; improved QoL; flexibility of new treatments; and accessibility of transport. This study has shown that it is possible to recruit and retain patents into a single-arm study of ESWT for DFUs. This study supports development of a large randomised control trial to determine the clinical and cost-effectiveness of ESWT for DFU healing.

Identifiants

pubmed: 36930191
doi: 10.12968/jowc.2023.32.3.182
doi:

Types de publication

Journal Article

Langues

eng

Pagination

182-192

Auteurs

Louise H Hitchman (LH)

Hull York Medical School, UK.
Hull University Teaching Hospitals NHS Trust, UK.

Joshua P Totty (JP)

Hull York Medical School, UK.
Pinderfields Hospital, UK.

Paris Cai (P)

Leeds University Teaching Hospitals, UK.

George E Smith (GE)

Hull York Medical School, UK.
Hull University Teaching Hospitals NHS Trust, UK.

Daniel Carradice (D)

Hull York Medical School, UK.
Hull University Teaching Hospitals NHS Trust, UK.

Ian C Chetter (IC)

Hull York Medical School, UK.
Hull University Teaching Hospitals NHS Trust, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH